查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356795

自体免疫肝炎诊断与治疗市场报告：2030 年趋势、预测与竞争分析

Autoimmune Hepatitis Diagnosis and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

自体自体免疫肝炎诊断和治疗的趋势和预测

至2030年，全球自体免疫肝炎诊断和治疗市场预计将达到3亿美元，2024年至2030年年复合成长率为5.3%。该市场的主要驱动因素是自体自体免疫肝炎盛行率的增加、医疗基础设施投资的增加、诊断工具的改进和技术进步。全球自体自体免疫肝炎诊断和治疗市场的未来对于医院/诊所、诊断中心和研究机构市场来说是充满希望的。

自体免疫肝炎诊断与治疗市场洞察

Lucintel 预测，由于对疾病早期检测的需求不断增加、临床应用不断扩大以及患有慢性病的老年人口迅速增长，影像检查将在预测期内实现最高增长。

在这个市场中，医院和诊所仍将是最大的部分。

由于酒精消费量增加、非法药物使用、肝病患者迅速增加以及政府机构和私人组织提高意识活动，北美在预测期内可能仍然是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.1.1.过去年度发生了哪些类型的併购，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球自体免疫肝炎诊断与治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球自体自体免疫肝炎诊断及治疗市场趋势（2018-2023）及预测（2024-2030）
  • 按类型分類的全球自体免疫肝炎诊断与治疗市场
    • Ⅰ型
    • II型
    • 变异型AIH
  • 全球自体自体免疫肝炎诊断与治疗市场（按诊断）
    • 验血
    • 影像检查
    • 切片检查
  • 按治疗分類的全球自体免疫肝炎诊断与治疗市场
    • 药品
    • 皮质类固醇
    • 免疫系统抑制剂
    • 肝臟移植
  • 按最终用途产业分類的全球自体自体免疫肝炎诊断与治疗市场
    • 医院和诊所
    • 诊断中心
    • 调查机构
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球自体自体免疫肝炎诊断与治疗市场（按地区）
  • 北美自体免疫肝炎诊断与治疗市场
  • 欧洲自体免疫肝炎诊断与治疗市场
  • 亚太地区自体自体免疫肝炎诊断与治疗市场
  • 其他地区自体免疫肝炎诊断与治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球自体自体免疫肝炎诊断与治疗市场成长机会（按类型）
    • 全球自体免疫肝炎诊断与治疗市场诊断成长机会
    • 全球自体免疫肝炎诊断与治疗市场的治疗成长机会
    • 最终用途行业的全球自体自体免疫肝炎诊断和治疗市场成长机会
    • 全球自体自体免疫肝炎诊断与治疗市场成长机会（按地区）
  • 全球自体自体免疫肝炎诊断与治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球自体免疫肝炎诊断和治疗市场的能力
    • 全球自体自体免疫肝炎诊断与治疗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Abbott Laboratories
  • AbbVie
  • Arihantanam Life Care
  • AstraZeneca PLC
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla
简介目录

Autoimmune Hepatitis Diagnosis and Treatment Trends and Forecast

The future of the global autoimmune hepatitis diagnosis and treatment market looks promising with opportunities in the hospital & clinic, diagnostic centre, and research institution markets. The global autoimmune hepatitis diagnosis and treatment market is expected to reach an estimated $0.3 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are increase in the prevalence of autoimmune hepatitis, rise investment for healthcare infrastructure ,and improved diagnostic tools and technological advancements.

A more than 150-page report is developed to help in your business decisions.

Autoimmune Hepatitis Diagnosis and Treatment by Segment

The study includes a forecast for the global autoimmune hepatitis diagnosis and treatment by type, diagnosis, treatment, end use industry, and region.

Autoimmune Hepatitis Diagnosis and Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Type-I
  • Type-II
  • Variant AIH

Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Test
  • Imaging Test
  • Liver Biopsy

Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Corticosteroids
  • Immune System Suppressors
  • Liver Transplant

Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Diagnostic Centre
  • Research Institutions
  • Others

Autoimmune Hepatitis Diagnosis and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Autoimmune Hepatitis Diagnosis and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies autoimmune hepatitis diagnosis and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autoimmune hepatitis diagnosis and treatment companies profiled in this report include-

  • Abbott Laboratories
  • Abbvie
  • Arihantanam Life Care
  • Astrazeneca Plc
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla

Autoimmune Hepatitis Diagnosis and Treatment Market Insights

Lucintel forecasts that imaging test is expected to witness highest growth over the forecast period due to the increasing requirement for early disease detection, an expanding range of clinical applications, and the rapidly growing elderly population afflicted by chronic ailments.

Within this market, hospitals & clinics will remain the largest segment.

North America will remain the largest region over the forecast period due to heightened alcohol consumption, illicit drug use, a surge in liver disease cases, and growing awareness campaigns conducted by both governmental and private organizations.

Features of the Global Autoimmune Hepatitis Diagnosis and Treatment Market

Market Size Estimates: Autoimmune hepatitis diagnosis and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Autoimmune hepatitis diagnosis and treatment market by various segments, such as by type, diagnosis, treatment, end use industry and region in terms of($B).

Regional Analysis: Autoimmune hepatitis diagnosis and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, diagnosis, treatments, end use industries, and region.s for the autoimmune hepatitis diagnosis and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autoimmune hepatitis diagnosis and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the autoimmune hepatitis diagnosis and treatment market size?

Answer: The global autoimmune hepatitis diagnosis and treatment market is expected to reach an estimated $0.3 billion by 2030.

Q.2. What is the growth forecast for autoimmune hepatitis diagnosis and treatment market?

Answer: The global autoimmune hepatitis diagnosis and treatment market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the autoimmune hepatitis diagnosis and treatment market?

Answer: The major drivers for this market are increase in the prevalence of autoimmune hepatitis, rise investment for healthcare infrastructure, and improved diagnostic tools and technological advancements.

Q.4. What are the major segments for autoimmune hepatitis diagnosis and treatment market?

Answer: The future of the autoimmune hepatitis diagnosis and treatment market looks promising with opportunities in the hospital & clinic, diagnostic centre, and research institution markets.

Q.5. Who are the key Autoimmune Hepatitis Diagnosis and Treatment Market companies?

Answer: Some of the key autoimmune hepatitis diagnosis and treatment companies are as follows:

  • Abbott Laboratories
  • AbbVie
  • Arihantanam Life Care
  • AstraZeneca PLC
  • Bayer
  • Biocon
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • Cipla

Q.6. Which autoimmune hepatitis diagnosis and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that imaging test is expected to witness highest growth over the forecast period due to the increasing requirement for early disease detection, an expanding range of clinical applications, and the rapidly growing elderly population afflicted by chronic ailments.

Q.7. In autoimmune hepatitis diagnosis and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to heightened alcohol consumption, illicit drug use, a surge in liver disease cases, and growing awareness campaigns conducted by both governmental and private organizations.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the autoimmune hepatitis diagnosis and treatment market by type (type-I, type-II, and variant AIH), diagnosis (blood test, imaging test, and liver biopsy), treatment (medication, corticosteroids, immune system suppressors, and liver transplant), end use industry (hospitals & clinics, diagnostic centre, research institutions, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.1. 1. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Autoimmune Hepatitis Diagnosis and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Autoimmune Hepatitis Diagnosis and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Type
    • 3.3.1: Type-I
    • 3.3.2: Type-II
    • 3.3.3: Variant AIH
  • 3.4: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis
    • 3.4.1: Blood Test
    • 3.4.2: Imaging Test
    • 3.4.3: Liver Biopsy
  • 3.5: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment
    • 3.5.1: Medication
    • 3.5.2: Corticosteroids
    • 3.5.3: Immune System Suppressors
    • 3.5.4: Liver Transplant
  • 3.6: Global Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Diagnostic Centre
    • 3.6.3: Research Institutions
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Autoimmune Hepatitis Diagnosis and Treatment Market by Region
  • 4.2: North American Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.2.1: North American Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.2.2: North American Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.3: European Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.3.1: European Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.3.2: European Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.4: APAC Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.4.1: APAC Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.4.2: APAC Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others
  • 4.5: ROW Autoimmune Hepatitis Diagnosis and Treatment Market
    • 4.5.1: ROW Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis: Blood Test, Imaging Test, and Liver Biopsy
    • 4.5.2: ROW Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry: Hospitals & Clinics, Diagnostic Centre, Research Institutions, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by End Use Industry
    • 6.1.5: Growth Opportunities for the Global Autoimmune Hepatitis Diagnosis and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Autoimmune Hepatitis Diagnosis and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Autoimmune Hepatitis Diagnosis and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Autoimmune Hepatitis Diagnosis and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott Laboratories
  • 7.2: AbbVie
  • 7.3: Arihantanam Life Care
  • 7.4: AstraZeneca PLC
  • 7.5: Bayer
  • 7.6: Biocon
  • 7.7: Bio-Rad Laboratories
  • 7.8: Bristol-Myers Squibb
  • 7.9: Cipla